Nesta página
01RMTI preço
02Instantâneo
03Gráfico
04Divisões de Ações
05Sobre
06Desempenho
07Avaliação e rácios
14Lucros
15Fundamentos Completos
16Demonstrações
17Investidores institucionais (13F)
18Ativistas e proprietários de 5%+
19Executivos da empresa
20Participação em ETFs
21Consenso
22Pares
26Minhas Métricas
RMTI Rockwell Medical, Inc. - Common Stock
NASDAQ · Health Care · Ver em SEC EDGAR ↗ fechar Out 2, 2026 10-K/10-Q Ago 13, 2026
$8,65
· % da faixa de 52 semanas
· acima do mínimo
· para alta
$0,60mínima 52 sem
$8,90máxima 52 sem
Capitalização de Mercado (MRQ)
$34M
P/E (TTM)
-10.8
EPS (TTM)
$-0.80
Receita (TTM)
$69M
seus distintivos
Intervalo 52 Semanas
$1–$9
Classificação do Analista
BUY
Preço-Alvo
$20
P/E
-10.8
ROE
-15.5%
Margem de Lucro Líquido
-7.3%
Sua barra de distintivos está vazia — fixe uma métrica em qualquer lugar desta página.
RMTI Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$8.65
Capitalização de Mercado (MRQ)
$34M
P/E (TTM)
-10.8
EPS (TTM)
$-0.80
Receita (TTM)
$69M
ROE (TTM)
-15.5%
Dívida/Capital (MRQ)
0.3
Intervalo 52 Semanas
$1–$9
RMTI Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
intervalo
barras
A granularidade da barra se adapta ao período selecionado — passe o mouse sobre o gráfico para ver a abertura/máxima/mínima/fechamento de uma barra.
Divisões de Ações
| Data ex | Desdobramento | Tipo |
|---|---|---|
| 1 de Julho de 2026 | 1-for-10 | Reverso |
| 13 de Maio de 2022 | 1-for-11 | Reverso |
Sobre Rockwell Medical, Inc. - Common Stock Visão geral da empresa da Wikipedia
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
The company's primary customers are dialysis providers.
Products
Triferic
Triferic was approved by the Food and Drug Administration (FDA) in January 2015. Triferic is the only FDA-approved therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients with chronic kidney disease. Triferic replaces the iron lost during hemodialysis treatments. Triferic delivers iron directly to transferrin which transports it to the bone marrow to make hemoglobin. Rockwell is actively marketing and commercializing Triferic in the U.S. hemodialysis market. In February 2014, the Company completed its long-term safety study for Triferic.
Rockwell Medical began commercializing Triferic (dialysate) and Triferic AVNU (intravenous) in the United States in the second half of 2019 and in early 2021, respectively. Triferic was launched into a very competitive marketplace with well-entrenched products and a lack of consensus regarding unmet medical needs for dialysis patients with anemia. Due to its limited market adoption, unfavorable reimbursement, and absence of interest from other companies to license or acquire Triferic despite Rockwell's significant effort to partner the program, Rockwell Medical discontinued its New Drug Applications (“NDAs”) for Triferic and Triferic AVNU in the United States in the fourth quarter of 2022.
Calcitriol
Calcitriol (active vitamin D) generic is FDA approved for treating secondary hyperparathyroidism or hypocalcemia in hemodialysis patients.
Hemodialysis Concentrates
Rockwell is a manufacturer of hemodialysis concentrates/dialysates for dialysis providers and distributors in the U.S. and globally. Hemodialysis concentrates remove toxins and replace critical nutrients in the dialysis patient's bloodstream during hemodialysis. Rockwell has three U.S. manufacturing and distribution facilities.
Iron (III) pyrophosphate
One of the main treatments that the company develops is iron (III) pyrophosphate, for iron supplementation, a key element in the formation of new red blood cells. It was licensed in 2011 for the delivery of iron supplementation for patients who suffer from anemic dialysis since the process accounts for treatment in around 90% of anemia patients.
International Partnerships
While Rockwell has discontinued commercialization of Triferic in the United States, the company has established international partnerships with companies seeking to develop and commercialize Triferic outside the United States and is working closely with these international partners to develop and commercialize Triferic in their respective regions.
South Korea for example; Triferic and Triferic AVNU have been approved in South Korea, and our partner, Jeil Pharmaceutical, launched Triferic in South Korea during the third quarter of 2022.
Also, in April 2023, Drogsan submitted a Marketing Authorization application and GMP application for Triferic AVNU to the Turkish Medicines and Medical Devices Agency ("TMMDA"), for which Drogsan received priority status and high priority status, respectively. Taking into consideration that Drogsan was granted an accelerated review for Triferic AVNU with the Turkish regulatory authority, Rockwell anticipates approval for Triferic AVNU in Turkey in 2024. Drogsan is responsible for all regulatory approval and commercialization activities.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
setorHealth Care
indústriaHealth Care
funcionários157
paísUS
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita$69M2016-12-31 → 2025-12-31
EPS$-0.152016-12-31 → 2025-12-31
Fluxo de caixa livre$-1M2024-12-31 → 2025-12-31
Margem líquida-7.3%2016-12-31 → 2025-12-31
Avaliação e Proporções
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
| Métrica | Tendência de 5 anos | RMTI | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| P/E (TTM) | -10.8média 5A ≈-16.1 | ≈-16.1 | · | · | |
| P/S (TTM) | 0.5média 5A ≈1.8 | ≈1.8 | 1.9 | Subvalorizado | |
| P/B (MRQ) | 1.0média 5A ≈34.7 | ≈34.7 | 0.8 | Subvalorizado | |
| EV / EBITDA | -12.9média 5A ≈-3.1 | ≈-3.1 | · | · | |
| Preço / FCF (TTM) | 22.3 | · | · | · | |
| Preço / Fluxo de Caixa (TTM) | 11.9média 5A ≈-10.5 | ≈-10.5 | · | · | |
| EV / Revenue (EV / Receita) | 0.5média 5A ≈1.8 | ≈1.8 | · | · | |
| EV / FCF | -26.9 | · | · | · | |
| Preço / Valor Patrimonial Tangível (MRQ) | 1.3média 5A ≈54.8 | ≈54.8 | · | · |
A mediana dos pares é calculada em uma base padronizada por métrica e pode não corresponder sempre à base TTM/MRQ mostrada para esta ação.
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
| Métrica | Tendência de 5 anos | RMTI | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Margem Bruta (TTM) | 17.7%média 5A ≈9.2% | ≈9.2% | 39.2% | Fraco | |
| Margem Operacional (TTM) | -6.5%média 5A ≈-17.2% | ≈-17.2% | -40.8% | Primeira linha | |
| Margem EBITDA (TTM) | -3.5%média 5A ≈-15.5% | ≈-15.5% | -23.4% | Primeira linha | |
| Pretax Margin (Margem de Impostos Pré-Tributação) | -7.7% | · | -35.6% | Primeira linha | |
| Margem de Lucro Líquido (TTM) | -7.3%média 5A ≈-19.3% | ≈-19.3% | -47.1% | Primeira linha | |
| ROA (TTM) | -9.3%média 5A ≈-23.6% | ≈-23.6% | -29.3% | Primeira linha | |
| ROE (TTM) | -15.5%média 5A ≈-132.0% | ≈-132.0% | -72.5% | Primeira linha | |
| ROIC | -10.2% | · | -17.5% | Primeira linha |
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
| Métrica | Tendência de 5 anos | RMTI | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido (MRQ) | 0.3média 5A ≈1.9 | ≈1.9 | · | · | |
| Índice de liquidez corrente (MRQ) | 3.3média 5A ≈2.4 | ≈2.4 | 4.1 | Baixa liquidez | |
| Quick Ratio (Índice de Liquidez Seca) | 2.0média 5A ≈1.3 | ≈1.3 | 2.8 | Baixa liquidez | |
| Dívida de Longo Prazo / Patrimônio Líquido (MRQ) | 0.2média 5A ≈1.3 | ≈1.3 | · | · |
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
| Métrica | Tendência de 5 anos | RMTI | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Revenue YoY (Receita Ano a Ano) | -31.8%média 5A ≈4.3% | ≈4.3% | · | · | |
| Revenue CAGR 3Y (CAGR Receita 3A) | -1.7%média 5A ≈8.9% | ≈8.9% | · | · | |
| Revenue CAGR 5Y (CAGR Receita 5A) | 2.2% | · | · | · |
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
| Métrica | Tendência de 5 anos | RMTI | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Asset Turnover (Giro do Ativo) | 1.2média 5A ≈1.4 | ≈1.4 | 0.4 | Primeira linha | |
| Inventory Turnover (Giro de Estoque) | 12.5média 5A ≈14.0 | ≈14.0 | 2.0 | Primeira linha | |
| Receivables Turnover (Giro de Contas a Receber) | 8.4média 5A ≈10.6 | ≈10.6 | 7.9 | Primeira linha | |
| Revenue / Employee (Receita anual ÷ funcionários (número de funcionários reportado, yfinance). Derivado — não é um conceito SEC-XBRL armazenado.) | ≈$441.1K | · | · | · |
valor · ≈ média 5A · mediana do setor · veredicto relativo à mediana
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
-61.6%
Próximo relatório
Nov 10, 2026
| Período | Relatório | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|---|
| 30 de Junho de 2026 | Ago 13, 2026 | $-0.34 | $-0.24 | -41.8% |
| 31 de Março de 2026 | Mai 7, 2026 | $-0.40 | $-0.26 | -56.9% |
| 31 de Dezembro de 2025 | $-0.10 | $0.20 | -149.0% | |
| 30 de Setembro de 2025 | $-0.50 | $-0.46 | -8.9% | |
| 30 de Junho de 2025 | $-0.50 | $-0.51 | 2.0% | |
| 31 de Março de 2025 | $-0.04 | $-0.05 | 21.6% | |
| 31 de Dezembro de 2024 | $-0.02 | $0.02 | -198.0% |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $69M | $101M | $84M | $73M | $62M | $62M | $61M | $63M | $57M | $53M | $55M | $54M | |
| Cost of Revenue | $58M | $84M | $75M | $69M | $64M | $59M | $58M | $65M | $54M | $47M | $46M | $46M | |
| Gross Profit | $12M | $17M | $9M | $4M | $-2M | $3M | $3M | $-2M | $4M | $7M | $9M | $9M | |
| R&D Expense | $0 | $19.0K | $1M | · | · | · | · | $6M | $6M | $6M | $5M | $8M | |
| SG&A Expense | $14M | $14M | $12M | $16M | $15M | $16M | $21M | $22M | $23M | $21M | $19M | $18M | |
| Operating Income | $-5M | $608.0K | $-7M | $-17M | $-30M | $-28M | $-35M | $-32M | $-26M | $-20M | $-15M | $-18M | |
| Interest Expense | · | · | $2M | $2M | $2M | $2M | $25.0K | · | · | · | · | · | |
| Interest Income | · | · | $211.0K | $33.0K | $22.0K | $238.0K | $392.0K | · | · | · | · | · | |
| Other Non-op | $-623.0K | $-1M | $-2M | $-2M | $-2M | $-2M | $397.0K | $313.3K | $1.6K | · | · | · | |
| Pretax Income | $-5M | $-480.0K | $-8M | · | · | · | · | · | $-26M | $-19M | $-14M | $-21M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $404.5K | $0 | $0 | |
| Net Income | $-5M | $-480.0K | $-8M | $-19M | $-33M | $-31M | $-34M | $-32M | $-26M | $-20M | $-14M | $-21M | |
| EPS (Basic) | $-0.15 | $-0.03 | $-0.37 | $-1.31 | $-3.83 | $-0.41 | · | · | $-0.51 | $-0.39 | $-0.29 | $-0.52 | |
| EPS (Diluted) | $-0.15 | $-0.03 | $-0.37 | $-1.31 | $-3.83 | $-0.41 | · | · | $-0.51 | $-0.39 | $-0.29 | $-0.52 | |
| Shares (Basic) | 35,974,231 | 31,058,539 | 23,322,915 | 14,304,512 | 8,526,186 | 75,621,674 | · | · | 51,067,412 | 50,676,180 | 50,068,129 | 41,404,999 | |
| Shares (Diluted) | 35,974,231 | 31,058,539 | 23,322,915 | 14,304,512 | 8,526,186 | 75,621,674 | · | · | 51,067,412 | 50,676,180 | 50,068,129 | 41,404,999 | |
| EBITDA | $-2M | $3M | $-5M | $-16M | $-30M | $-28M | $-34M | $-32M | $-25M | $-19M | $-14M | $-17M |
Balanço Patrimonial
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11M | $16M | $9M | $10M | $13M | $49M | $12M | $23M | $8M | $17M | $31M | $66M | |
| Short-term Investments | · | · | · | · | · | · | · | $11M | $25M | $41M | $39M | $20M | |
| Receivables | $8M | $8M | $11M | $6M | $6M | $4M | $4M | $7M | $6M | $6M | $5M | $4M | |
| Inventory | $3M | $6M | $6M | $6M | $4M | $4M | $4M | $4M | $8M | $12M | $8M | $4M | |
| Prepaid Expense | $2M | $1M | $1M | $2M | $3M | $3M | $3M | $2M | $2M | · | · | · | |
| Other Current Assets | · | · | · | · | · | · | · | · | $2M | $2M | $1M | $587.2K | |
| Current Assets | $38M | $37M | $29M | $35M | $35M | $69M | $37M | $47M | $49M | $79M | $85M | $95M | |
| PP&E (Net) | $5M | $6M | $6M | $2M | $2M | $3M | $2M | $3M | $3M | $1M | $2M | $1M | |
| PP&E (Gross) | $15M | $16M | $15M | $10M | $10M | $9M | $8M | $9M | $12M | $11M | $11M | $10M | |
| Accum. Depreciation | $11M | $10M | $9M | $8M | $7M | $7M | $6M | $6M | $9M | $10M | $9M | $9M | |
| Goodwill | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $920.7K | $920.7K | $920.7K | $920.7K | $920.7K | |
| Intangibles | $10M | $10M | $11M | $0 | · | · | · | · | $4.0K | $4.4K | $165.7K | $332.7K | |
| Other Non-current Assets | $556.0K | $528.0K | $527.0K | $523.0K | $619.0K | $629.0K | $435.0K | $536.5K | $494.8K | $501.2K | $462.8K | $542.2K | |
| Total Assets | $57M | $59M | $52M | $47M | $49M | $78M | $44M | $53M | $59M | $83M | $88M | $98M | |
| Accounts Payable | $2M | $3M | $5M | $4M | $4M | $4M | $3M | $4M | $4M | $6M | $4M | $5M | |
| Accrued Liabilities | $4M | $6M | $7M | $8M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | $4M | |
| Current Liabilities | $10M | $14M | $17M | $18M | $21M | $13M | $12M | $13M | $9M | $10M | $8M | $10M | |
| Capital Leases | $1M | $2M | $1M | $3M | · | $2M | $2M | · | · | · | · | · | |
| Other Non-current Liabilities | · | $0 | $14.0K | $14.0K | $14.0K | $0 | · | · | · | · | · | · | |
| Total Liabilities | $20M | $27M | $31M | $33M | $46M | $44M | $24M | $25M | $26M | · | · | · | |
| Long-term Debt | $9M | · | $8M | $9M | $21M | $21M | · | · | · | · | · | · | |
| Total Debt | $9M | $8M | $8M | $9M | $21M | $21M | · | · | · | · | · | · | |
| Common Stock | · | · | · | · | · | · | · | · | · | $268M | $258M | $249M | |
| Paid-in Capital | $440M | $430M | $418M | $403M | $373M | $372M | $327M | $300M | · | · | · | · | |
| Retained Earnings | $-403M | $-398M | $-397M | $-389M | $-370M | $-337M | $-307M | $-272M | $-240M | $-214M | $-195M | $-180M | |
| AOCI | $131.0K | $54.0K | $-1.0K | $163.0K | $52.0K | $57.0K | $52.0K | $63.1K | $-35.4K | $-902.5K | $-915.5K | $-197.7K | |
| Stockholders' Equity | $37M | $33M | $21M | $14M | $3M | $34M | $20M | $27M | $33M | $53M | $62M | $69M | |
| Liabilities + Equity | $57M | $59M | $52M | $47M | $49M | $78M | $44M | $53M | $59M | $83M | $88M | $98M | |
| Shares Outstanding | 3,940,530 | 3,405,692 | 29,130,607 | 12,163,673 | 8,544,225 | 8,506,651 | 65,378,890 | 57,034,154 | 51,768,424 | 51,527,711 | 51,501,877 | 50,284,007 |
Fluxo de Caixa
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $2M | $1M | $576.0K | $668.0K | $834.0K | $788.0K | $650.1K | $514.4K | $762.4K | $822.3K | $996.3K | |
| Stock-based Comp | $2M | $1M | $932.0K | $315.0K | $943.0K | $475.0K | $5M | $4M | $7M | $10M | $9M | $10M | |
| Amort. of Intangibles | · | · | $300.0K | · | · | · | · | · | · | · | · | · | |
| Restructuring | $1M | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | $-966.0K | $-317.0K | $-11M | $-2M | $-7M | $-3M | $-887.5K | $3M | $-6M | $-8M | $-20M | $27M | |
| Operating Cash Flow | $-659.0K | $4M | $-9M | $-17M | $-34M | $-30M | $-27M | $-20M | $-21M | $-12M | $-13M | $4M | |
| CapEx | $542.0K | $1M | $284.0K | · | · | · | · | · | · | · | · | · | |
| Investing Cash Flow | $-9M | $-5M | $-3M | $-2M | $311.0K | $3M | $-5M | $13M | $15M | $-2M | $-21M | $-9M | |
| Debt Issued | · | · | · | · | $0 | $22M | $0 | · | · | · | · | · | |
| Net Debt Issued | · | · | · | · | $0 | $22M | · | · | · | · | · | · | |
| Stock Issued | $8M | $10M | $15M | $15M | · | · | $5M | $22M | $123.6K | · | · | · | |
| Net Stock Activity | $8M | $10M | $15M | · | · | · | · | $22M | · | · | · | · | |
| Financing Cash Flow | $4M | $7M | $11M | $16M | $-2M | $63M | $21M | $22M | $-2M | $80.2K | $-132.7K | $58M | |
| Net Change in Cash | $-5M | $7M | $-1M | $-3M | $-35M | $37M | $-11M | $14M | $-9M | $-14M | $-35M | $54M | |
| Taxes Paid | $0 | · | · | · | · | · | · | · | · | $404.5K | · | · | |
| Free Cash Flow | $-1M | $3M | · | · | · | · | · | · | · | · | · | · |
Lucratividade
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 16.9% | 17.2% | 10.4% | 5.6% | -3.9% | 4.4% | 4.6% | -2.5% | 6.5% | 12.7% | 16.2% | 15.8% | |
| Operating Margin | -6.8% | 0.60% | -8.0% | -23.1% | -49.0% | -45.7% | -56.3% | -51.2% | -45.2% | -37.9% | -27.3% | -32.4% | |
| Net Margin | -7.7% | -0.47% | -10.1% | -25.7% | -52.8% | -49.7% | -55.7% | -50.7% | -45.2% | -37.2% | -26.1% | -39.4% | |
| Pretax Margin | -7.7% | -0.47% | · | · | · | · | · | · | -45.2% | -36.4% | -26.1% | -39.4% | |
| EBITDA Margin | -3.6% | 2.8% | -6.2% | -22.3% | -47.9% | -44.4% | -55.0% | -50.1% | -44.3% | -36.5% | -25.8% | -30.6% | |
| ROA | -9.1% | -0.86% | -17.1% | -39.2% | -51.7% | -50.6% | -70.5% | -57.7% | -36.5% | -23.2% | -15.5% | -31.8% | |
| ROE | -15.8% | -1.6% | -39.4% | -123.5% | -479.5% | -81.0% | -155.1% | -160.8% | -60.4% | -34.4% | -22.0% | -61.6% | |
| ROIC | -10.2% | 1.5% | · | · | · | · | · | · | -78.8% | -39.0% | -24.2% | -25.6% |
Liquidez e Solvência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.0 | 2.6 | 1.7 | 2.0 | 1.7 | 5.4 | 3.0 | 3.5 | 5.3 | 7.7 | 10.5 | 9.7 | |
| Quick Ratio | 2.0 | 1.7 | 1.2 | 0.9 | 0.9 | 4.1 | 1.3 | 3.1 | 4.3 | 6.3 | 9.4 | 9.2 | |
| Debt / Equity | 0.2 | 0.3 | 0.4 | 0.7 | 8.1 | 0.6 | · | · | · | · | · | · | |
| LT Debt / Equity | 0.2 | 0.3 | 0.4 | 0.5 | 5.2 | 0.6 | · | · | · | · | · | · | |
| Interest Coverage | · | · | -2.9 | -8.7 | -12.9 | -15.1 | · | · | · | · | · | · |
Eficiência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.2 | 1.8 | 1.7 | 1.5 | 1.0 | 1.0 | 1.3 | 1.1 | 0.8 | 0.6 | 0.6 | 0.8 | |
| Inventory Turnover | 12.5 | 14.4 | 12.8 | 13.9 | 16.1 | 15.7 | 15.2 | 11.1 | 5.4 | 4.7 | 7.9 | 13.6 | |
| Receivables Turnover | 8.4 | 10.6 | 9.7 | 12.0 | 12.3 | 14.9 | 11.0 | 9.5 | 9.0 | 9.3 | 11.6 | 12.0 |
Por Ação
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.94 | $0.96 | $0.73 | $1.16 | $0.03 | $0.37 | $0.31 | $0.48 | $0.64 | $1.03 | $1.21 | $1.37 | |
| Revenue / Share | $1.93 | $3.27 | $3.58 | $7.38 | $0.66 | · | · | · | $1.12 | $1.05 | $1.11 | $1.31 | |
| Cash Flow / Share | $-0.02 | $0.14 | $-0.40 | $-1.76 | $-0.36 | · | · | · | $-0.41 | $-0.25 | $-0.32 | $0.10 | |
| Cash / Share | $0.27 | $0.46 | $0.31 | $0.83 | $0.14 | $0.52 | $0.18 | $0.40 | $0.16 | $0.33 | $0.61 | $1.31 | |
| EPS (TTM) | $-0.15 | $-0.03 | $-0.37 | $-1.31 | $-3.83 | $-0.41 | $-0.46 | $-0.46 | $-0.51 | $-0.39 | $-0.29 | $-0.52 |
Taxas de Crescimento
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -31.8% | 21.4% | 14.8% | 17.6% | -0.43% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -1.7% | 17.9% | 10.4% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 2.2% | · | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM)
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $69M | $101M | $84M | $73M | $62M | $62M | $61M | $63M | $57M | $53M | $55M | $54M | |
| Net Income TTM | $-5M | $-480.0K | $-8M | $-19M | $-33M | $-31M | $-34M | $-32M | $-26M | $-20M | $-14M | $-21M | |
| Market Cap | $33M | $69M | $55M | $12M | $424M | $1.04B | $1.75B | $1.42B | $3.31B | $3.71B | $5.80B | $5.69B | |
| Enterprise Value | $31M | $62M | $54M | $11M | $431M | $1.01B | · | · | · | · | · | · | |
| P/E | -5.5 | -68.0 | -5.1 | -0.8 | -1.2 | -27.1 | -58.3 | -54.0 | -125.5 | -184.7 | -388.4 | -217.5 | |
| P/S | 0.5 | 0.7 | 0.7 | 0.2 | 6.8 | 16.7 | 28.6 | 22.4 | 57.8 | 69.7 | 104.8 | 104.9 | |
| P/B | 0.9 | 2.1 | 2.6 | 0.9 | 167.2 | 30.4 | 86.4 | 52.0 | 100.7 | 70.1 | 93.1 | 82.8 | |
| P / Tangible Book | 1.2 | 3.2 | 5.7 | 0.9 | 262.6 | 31.3 | · | · | · | · | · | · | |
| P / Cash Flow | -49.6 | 16.5 | -5.8 | -0.7 | -12.6 | -35.1 | -64.3 | -69.4 | -157.0 | -298.1 | -357.2 | 1335.5 | |
| P / FCF | -27.2 | 21.8 | · | · | · | · | · | · | · | · | · | · | |
| EV / EBITDA | -12.3 | 22.3 | -10.4 | -0.7 | -14.5 | -36.7 | · | · | · | · | · | · | |
| EV / FCF | -25.7 | 19.5 | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 0.4 | 0.6 | 0.7 | 0.2 | 7.0 | 16.3 | · | · | · | · | · | · | |
| Earnings Yield | -18.1% | -1.5% | -19.6% | -129.7% | -84.9% | -3.7% | -1.7% | -1.8% | -0.80% | -0.54% | -0.26% | -0.46% |
Demonstração de Resultados
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $18M | $17M | $18M | $16M | $16M | $19M | $25M | $28M | $26M | $23M | $22M | $24M | $18M | $20M | $19M | $19M | |
| Cost of Revenue | $15M | $14M | $14M | $14M | $14M | $16M | $21M | $22M | $21M | $20M | $19M | $22M | $17M | $17M | $17M | $18M | |
| Gross Profit | $3M | $3M | $4M | $2M | $3M | $3M | $4M | $6M | $5M | $3M | $3M | $2M | $1M | $3M | $2M | $777.0K | |
| R&D Expense | $40.0K | · | $0 | $0 | $0 | $0 | $1.0K | $0 | $0 | $18.0K | $168.0K | $494.0K | $167.0K | $278.0K | · | $469.0K | |
| SG&A Expense | $4M | $4M | $4M | $3M | $3M | $4M | $3M | $4M | $3M | $4M | $3M | $3M | $3M | $3M | $4M | $3M | |
| Operating Income | $-1M | $-1M | $-398.0K | $-2M | $-1M | $-1M | $-519.0K | $2M | $515.0K | $-1M | $-547.0K | $-2M | $-3M | $-1M | $-2M | $-4M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $431.0K | · | $411.0K | $395.0K | $387.0K | $435.0K | $476.0K | |
| Other Non-op | $-111.0K | $-125.0K | $-156.0K | $-169.0K | $-143.0K | $-155.0K | $-237.0K | $-272.0K | $-172.0K | $-407.0K | $-965.0K | $-135.0K | $-346.0K | $-323.0K | $-396.0K | $-482.0K | |
| Net Income | $-1M | $-2M | $-554.0K | $-2M | $-1M | $-2M | $-756.0K | $2M | $343.0K | $-2M | $-2M | $-2M | $-3M | $-2M | $-2M | $-4M | |
| EPS (Basic) | $-0.34 | $-0.04 | $-0.01 | $-0.05 | $-0.48 | $-0.04 | $-0.03 | $0.05 | $0.01 | $-0.06 | $-0.02 | $-0.07 | $-0.18 | $-0.10 | $0.19 | $-0.23 | |
| EPS (Diluted) | $-0.70 | $-0.04 | $-0.01 | $-0.05 | $-0.05 | $-0.04 | $-0.02 | $0.04 | $0.01 | $-0.06 | $-0.02 | $-0.07 | $-0.18 | $-0.10 | $0.19 | $-0.23 | |
| Shares (Basic) | 3,958,568 | 39,418,302 | · | 36,024,940 | 3,431,130 | 34,107,640 | · | 31,551,805 | 30,451,622 | 29,327,204 | · | 27,521,088 | 18,496,640 | 18,359,940 | · | 18,463,673 | |
| Shares (Diluted) | 3,958,568 | 39,418,302 | · | 36,024,940 | 3,431,130 | 34,107,640 | · | 32,420,168 | 32,033,776 | 29,327,204 | · | 27,521,088 | 18,496,640 | 18,359,940 | · | 18,463,673 | |
| EBITDA | $-1M | $-969.0K | · | $-2M | $-1M | $-821.0K | · | $2M | $515.0K | $-779.0K | · | $-2M | $-3M | $-1M | · | $-4M |
Balanço Patrimonial
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11M | $10M | $11M | $14M | $12M | $11M | $16M | $12M | $12M | $7M | $9M | $8M | $9M | $11M | $10M | $13M | |
| Receivables | $8M | $9M | $8M | $8M | $8M | $10M | $8M | $9M | $11M | $11M | $11M | $9M | $5M | $6M | $6M | $7M | |
| Inventory | $3M | $3M | $3M | $4M | $4M | $5M | $6M | $6M | $6M | $6M | $6M | $5M | $6M | $6M | $6M | $5M | |
| Prepaid Expense | $441.0K | $1M | $2M | $2M | $943.0K | $988.0K | $1M | $1M | $1M | $910.0K | $1M | $2M | $1M | $1M | $2M | $2M | |
| Current Assets | $36M | $37M | $38M | $38M | $32M | $33M | $37M | $34M | $30M | $27M | $29M | $28M | $28M | $30M | $35M | $42M | |
| PP&E (Net) | $5M | $4M | $5M | $5M | $5M | $5M | $6M | $6M | $6M | $6M | $6M | $7M | $2M | $2M | $2M | $2M | |
| PP&E (Gross) | $14M | $14M | $15M | $16M | $16M | $16M | $16M | $16M | $16M | $15M | $15M | $15M | $10M | $10M | $10M | $10M | |
| Accum. Depreciation | $9M | $10M | $11M | $12M | $11M | $11M | $10M | $10M | $10M | $9M | $9M | $8M | $8M | $8M | $8M | $7M | |
| Goodwill | $920.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | |
| Intangibles | $9M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $11M | $11M | $11M | · | · | $0 | · | |
| Other Non-current Assets | $556.0K | $556.0K | $556.0K | $561.0K | $561.0K | $521.0K | $528.0K | $548.0K | $548.0K | $527.0K | $527.0K | $527.0K | $527.0K | $522.0K | $523.0K | $522.0K | |
| Total Assets | $57M | $57M | $57M | $57M | $53M | $54M | $59M | $57M | $53M | $51M | $52M | $53M | $38M | $40M | $47M | $54M | |
| Accounts Payable | $3M | $3M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $5M | $5M | $4M | $6M | $5M | $4M | $3M | |
| Accrued Liabilities | $4M | $3M | $4M | $4M | $4M | $5M | $6M | $6M | $6M | $5M | $7M | $7M | $4M | $4M | $8M | $6M | |
| Current Liabilities | $11M | $10M | $10M | $10M | $11M | $11M | $14M | $14M | $15M | $15M | $17M | $21M | $17M | $15M | $18M | $19M | |
| Capital Leases | $3M | $3M | $1M | $2M | $2M | $1M | $2M | $2M | $2M | $3M | $1M | $2M | $2M | $2M | $3M | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | |
| Total Liabilities | $21M | $22M | $20M | $20M | $22M | $22M | $27M | $28M | $30M | $30M | $31M | $31M | $29M | $28M | $33M | $38M | |
| Long-term Debt | $9M | $9M | · | · | · | · | · | · | · | · | · | $9M | $9M | $9M | $9M | $14M | |
| Total Debt | $9M | $9M | · | $9M | $9M | $9M | · | $8M | $8M | $8M | · | $9M | $9M | $9M | · | $14M | |
| Paid-in Capital | $441M | $440M | $440M | $439M | $431M | $431M | $430M | $426M | $422M | $420M | $418M | $417M | $403M | $403M | $403M | $402M | |
| Retained Earnings | $-406M | $-405M | $-403M | $-402M | $-401M | $-399M | $-398M | $-397M | $-399M | $-399M | $-397M | $-396M | $-394M | $-391M | $-389M | $-386M | |
| AOCI | $130.0K | $133.0K | $131.0K | $73.0K | $57.0K | $60.0K | $54.0K | $8.0K | $-5.0K | $24.0K | $-1.0K | $68.0K | $137.0K | $156.0K | $163.0K | $54.0K | |
| Stockholders' Equity | $35M | $36M | $37M | $37M | $30M | $32M | $33M | $29M | $23M | $21M | $21M | $22M | $10M | $13M | $14M | $16M | |
| Liabilities + Equity | $57M | $57M | $57M | $57M | $53M | $54M | $59M | $57M | $53M | $51M | $52M | $53M | $38M | $40M | $47M | $54M | |
| Shares Outstanding | 3,972,029 | 39,470,299 | 39,405,302 | 39,405,301 | 34,430,352 | 34,257,903 | 34,056,920 | 32,318,806 | 31,030,218 | 29,556,474 | 29,130,607 | 28,489,663 | 16,795,673 | 12,552,673 | 12,163,673 | 11,152,673 |
Fluxo de Caixa
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $492.0K | $511.0K | $546.0K | $544.0K | $563.0K | $539.0K | $543.0K | $543.0K | $549.0K | $545.0K | $550.0K | $564.0K | $170.0K | $160.0K | $154.0K | $143.0K | |
| Stock-based Comp | $403.0K | $479.0K | $457.0K | $532.0K | $382.0K | $445.0K | $382.0K | $321.0K | $338.0K | $251.0K | $218.0K | $212.0K | $309.0K | $193.0K | $220.0K | $177.0K | |
| Amort. of Intangibles | · | · | · | · | · | · | · | · | · | · | · | $100.0K | · | · | · | · | |
| Restructuring | · | · | $200.0K | $500.0K | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $448.0K | · | · | · | $-3M | · | · | · | $-1M | · | · | · | $-6M | · | · | |
| Operating Cash Flow | $2M | $-167.0K | $2M | $-1M | $2M | $-3M | $865.0K | $4M | $1M | $-2M | $-43.0K | $-4M | $-2M | $-4M | $-112.0K | $-1M | |
| CapEx | $617.0K | $425.0K | $86.0K | $229.0K | $164.0K | $63.0K | $395.0K | $191.0K | $286.0K | $139.0K | $43.0K | · | · | · | · | · | |
| Investing Cash Flow | $-487.0K | $-122.0K | $-4M | $-4M | $-103.0K | $-1.0K | $-332.0K | $-6M | $2M | $-139.0K | $2M | $-10M | $-64.0K | $5M | $3M | $-15M | |
| Stock Issued | · | · | $0 | $8M | $0 | $0 | $4M | $4M | $2M | $560.0K | $1M | $14M | $0 | $0 | $0 | $0 | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $560.0K | · | · | · | · | · | · | |
| Financing Cash Flow | $-683.0K | $-813.0K | $-1M | $7M | $-650.0K | $-783.0K | $3M | $2M | $2M | $178.0K | $-742.0K | $13M | $-130.0K | $-631.0K | $-6M | $-2M | |
| Net Change in Cash | $910.0K | $-1M | $-3M | $1M | $1M | $-4M | $3M | $475.0K | $5M | $-2M | $1M | $-1M | $-2M | $792.0K | $-3M | $-18M | |
| Free Cash Flow | · | $-592.0K | · | · | · | $-4M | · | · | · | · | · | · | · | · | · | · |
Lucratividade
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 18.2% | 16.7% | · | 14.3% | 15.6% | 16.1% | · | 22.0% | 17.6% | 13.5% | · | 9.3% | 5.7% | 13.2% | · | 4.2% | |
| Operating Margin | -6.0% | -8.5% | · | -10.0% | -8.4% | -7.2% | · | 6.8% | 2.0% | -5.8% | · | -7.3% | -16.4% | -7.3% | · | -19.8% | |
| Net Margin | -6.6% | -9.3% | · | -11.0% | -9.3% | -8.0% | · | 5.9% | 1.3% | -7.6% | · | -7.9% | -18.3% | -8.9% | · | -22.4% | |
| EBITDA Margin | -6.0% | -5.6% | · | -10.0% | -8.4% | -4.3% | · | 6.8% | 2.0% | -3.4% | · | -7.3% | -16.4% | -6.4% | · | -19.8% | |
| ROA | -2.1% | -2.9% | · | -3.1% | -2.8% | -2.9% | · | 3.0% | 0.75% | -3.8% | · | -3.5% | -6.8% | -4.5% | · | -7.4% | |
| ROE | -3.6% | -4.8% | · | -5.3% | -5.5% | -5.8% | · | 6.6% | 2.1% | -10.4% | · | -9.9% | -22.3% | -45.2% | · | -30.8% |
Liquidez e Solvência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.7 | · | 3.9 | 2.9 | 2.9 | · | 2.4 | 2.0 | 1.8 | · | 1.3 | 1.6 | 2.0 | · | 2.2 | |
| Quick Ratio | 1.7 | 1.9 | · | 2.3 | 1.9 | 1.9 | · | 1.5 | 1.5 | 1.2 | · | 0.8 | 0.8 | 1.1 | · | 1.1 | |
| Debt / Equity | 0.3 | 0.2 | · | 0.2 | 0.3 | 0.3 | · | 0.3 | 0.4 | 0.4 | · | 0.4 | 1.0 | 0.7 | · | 0.9 | |
| LT Debt / Equity | 0.2 | 0.2 | · | 0.2 | 0.3 | 0.3 | · | 0.3 | 0.4 | 0.4 | · | 0.2 | 0.5 | 0.5 | · | 0.6 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -3.1 | · | -4.2 | -7.5 | -3.7 | · | -7.8 |
Eficiência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.4 | · | 0.5 | 0.6 | 0.5 | · | 0.4 | 0.4 | 0.5 | · | 0.3 | |
| Inventory Turnover | 4.2 | 3.6 | · | 2.8 | 2.7 | 2.9 | · | 3.9 | 3.6 | 3.4 | · | 4.1 | 3.1 | 3.1 | · | 4.0 | |
| Receivables Turnover | 2.2 | 1.9 | · | 1.9 | 1.7 | 1.8 | · | 3.1 | 3.2 | 2.6 | · | 2.8 | 2.7 | 3.0 | · | 2.8 |
Por Ação
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $8.83 | $0.91 | · | $0.94 | $0.88 | $0.92 | · | $0.90 | $0.76 | $0.70 | · | $0.76 | $0.57 | $1.00 | · | $1.45 | |
| Revenue / Share | $4.49 | $0.44 | · | $0.44 | $0.47 | $0.55 | · | $0.87 | $0.81 | $0.77 | · | $0.86 | $0.98 | $1.07 | · | $1.78 | |
| Cash Flow / Share | · | $-0.00 | · | · | · | $-0.10 | · | · | · | $-0.08 | · | · | · | $-0.21 | · | · | |
| Cash / Share | $2.65 | $0.24 | · | $0.35 | $0.36 | $0.33 | · | $0.38 | $0.38 | $0.22 | · | $0.27 | $0.53 | $0.87 | · | $1.16 | |
| EPS (TTM) | $-0.80 | $-0.15 | · | $-0.16 | $-0.07 | $-0.01 | · | $-0.03 | $-0.14 | $-0.33 | · | $-0.16 | $-0.32 | $-0.57 | · | $-2.54 |
Avaliação (TTM)
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $69M | $68M | · | $76M | $88M | $98M | · | $99M | $94M | $87M | · | $81M | $76M | $76M | · | $69M | |
| Net Income TTM | $-5M | $-5M | · | $-6M | $-2M | $-264.0K | · | $-1M | $-5M | $-8M | · | $-9M | $-12M | $-13M | · | $-25M | |
| Market Cap | $22M | $35M | · | $47M | $29M | $39M | · | $128M | $55M | $49M | · | $59M | $92M | $23M | · | $15M | |
| Enterprise Value | $20M | $34M | · | $42M | $25M | $36M | · | $124M | $51M | $51M | · | $60M | $92M | $21M | · | $16M | |
| P/E | -6.9 | -5.9 | · | -7.5 | -12.1 | -113.0 | · | -132.3 | -12.6 | -5.0 | · | -13.0 | -17.1 | -3.2 | · | -0.5 | |
| P/S | 0.3 | 0.5 | · | 0.6 | 0.3 | 0.4 | · | 1.3 | 0.6 | 0.6 | · | 0.7 | 1.2 | 0.3 | · | 0.2 | |
| P/B | 0.6 | 1.0 | · | 1.3 | 1.0 | 1.2 | · | 4.4 | 2.3 | 2.4 | · | 2.8 | 9.6 | 1.8 | · | 0.9 | |
| P / Tangible Book | 0.9 | 1.4 | · | 1.8 | 1.5 | 1.9 | · | 7.2 | 4.5 | 5.4 | · | 6.1 | 10.7 | 2.0 | · | 1.0 | |
| P / Cash Flow | · | -210.4 | · | · | · | -11.1 | · | · | · | -20.6 | · | · | · | -5.9 | · | · | |
| EV / Revenue | 0.3 | 0.5 | · | 0.6 | 0.3 | 0.4 | · | 1.3 | 0.5 | 0.6 | · | 0.7 | 1.2 | 0.3 | · | 0.2 | |
| Earnings Yield | -14.5% | -16.9% | · | -13.3% | -8.2% | -0.88% | · | -0.76% | -8.0% | -19.9% | · | -7.7% | -5.9% | -31.5% | · | -192.4% |
Período mais recente à esquerda · valores nulos mostrados como ·
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Receita | $69M | $101M | $84M | $73M | $62M |
| Margem Bruta % | 16.9% | 17.2% | 10.4% | 5.6% | -3.9% |
| Margem Operacional % | -6.8% | 0.60% | -8.0% | -23.1% | -49.0% |
| Lucro líquido | $-5M | $-480.0K | $-8M | $-19M | $-33M |
| EPS Diluído | $-0.15 | $-0.03 | $-0.37 | $-1.31 | $-3.83 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido | 0.2 | 0.3 | 0.4 | 0.7 | 8.1 |
| Índice de liquidez corrente | 4.0 | 2.6 | 1.7 | 2.0 | 1.7 |
| Índice de Liquidez Seca | 2.0 | 1.7 | 1.2 | 0.9 | 0.9 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $-1M | $3M | · | · | · |
Investidores institucionais (13F) 36 declarantes · $3.0M total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Detentores
36
Valor detido
$3.0M
Novas posições
6
Posições encerradas
15
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 6 (-8 vs trimestre anterior) | 15 (+10 vs trimestre anterior) | 7 (-3 vs trimestre anterior) | 9 (0 vs trimestre anterior) | -598K |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| VANGUARD GROUP INC | $1.165.089 | 1.396.990 | 38,59% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $677.668 | 1.229.888 | 22,44% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $213.901 | 364.061 | 7,08% | Ações |
| RENAISSANCE TECHNOLOGIES LLC | $197.999 | 359.672 | 6,56% | Ações |
| JANE STREET GROUP, LLC | $134.998 | 245.229 | 4,47% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $128.196 | 232.660 | 4,25% | Ações |
| Wealthspire Advisors, LLC | $83.587 | 151.838 | 2,77% | Ações |
| BlackRock, Inc. | $79.688 | 144.756 | 2,64% | Ações |
| STATE STREET CORP | $55.548 | 100.904 | 1,84% | Ações |
| NORTHERN TRUST CORP | $50.570 | 91.862 | 1,67% | Ações |
| UBS Group AG | $38.505 | 70.010 | 1,28% | Ações |
| PANAGORA ASSET MANAGEMENT INC | $38.179 | 69.353 | 1,26% | Ações |
| CORSAIR CAPITAL MANAGEMENT, L.P. | $27.525 | 50.000 | 0,91% | Ações |
| LPL Financial LLC | $22.163 | 40.259 | 0,73% | Ações |
| WealthTrust Axiom LLC | $18.166 | 33.000 | 0,60% | Ações |
| Richmond Brothers, Inc. | $16.851 | 30.611 | 0,56% | Ações |
| Spartan Wealth Advisory Services LLC | $13.768 | 25.010 | 0,46% | Ações |
| TWO SIGMA SECURITIES, LLC | $13.621 | 24.743 | 0,45% | Ações |
| Tower Research Capital LLC (TRC) | $7.919 | 14.386 | 0,26% | Ações |
| Burford Brothers, Inc. | $7.799 | 14.168 | 0,26% | Ações |
| XTX Topco Ltd | $6.157 | 11.184 | 0,20% | Ações |
| Vanguard Global Advisers, LLC | $5.825 | 10.571 | 0,19% | Ações |
| Savvy Advisors, Inc. | $5.505 | 10.000 | 0,18% | Ações |
| WELLS FARGO & COMPANY/MN | $5.498 | 9.987 | 0,18% | Ações |
| MORGAN STANLEY | $2.379 | 4.321 | 0,08% | Ações |
| SHP Wealth Management | $782 | 1.421 | 0,03% | Ações |
| IFG Advisory, LLC | $369 | 670 | 0,01% | Ações |
| GROUP ONE TRADING LLC | $255 | 463 | 0,01% | Ações |
| OSAIC HOLDINGS, INC. | $244 | 445 | 0,01% | Ações |
| JONES FINANCIAL COMPANIES LLLP | $168 | 258 | 0,01% | Ações |
| COMERICA BANK | $136 | 163 | 0,00% | Ações |
| BARCLAYS PLC | $115 | 209 | 0,00% | Ações |
| FIFTH THIRD BANCORP | $90 | 163 | 0,00% | Ações |
| GSA CAPITAL PARTNERS LLP | $38 | 69.800 | 0,00% | Ações |
| Farther Finance Advisors, LLC | $21 | 39 | 0,00% | Ações |
| FMR LLC | $3 | 6 | 0,00% | Ações |
Ativistas e proprietários de 5%+ 15 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Richmond Brothers, Inc., RBI Private Investment I, LLC, RBI Private Investment II, LLC, The RBI Opportunities Fund, LLC, The RBI Opportunities Fund II, LLC, RBI PI Manager, LLC, Richmond Brothers 401(k) Profit Sharing Plan, David S. Richmond, Matthew J. Curfman ×18 declarações | 6 de Setembro de 2023 | · | Declaração inicial | · | SEC |
| Robert L. Chioini ×10 declarações | 29 de Dezembro de 2017 | · | Declaração inicial | · | SEC |
| David Hagelstein Charitable Remainder Unitrust dated November 20, 2003, as amended, David A. Hagelstein | 13 de Agosto de 2013 | · | Declaração inicial | · | SEC |
| Thomas E. Klema ×3 declarações | 1 de Julho de 2013 | · | Declaração inicial | · | SEC |
| Thomas E. Klema (2) | 23 de Março de 2012 | · | Declaração inicial | · | SEC |
| David Hagelstein Charitable Remainder Unitrust dated November 20, 2003, David A. Hagelstein | 8 de Dezembro de 2011 | · | Declaração inicial | · | SEC |
| David Hagelstein Charitable Remainder Unitrust Agreement, dated November 20, 2003, David A. Hagelstein, individually and the David A. Hagelstein Revocable Living Trust, dated October 27, 1993 ×4 declarações | 31 de Março de 2011 | · | Declaração inicial | Investimento passivo | SEC |
| Pessoa de relato não divulgada | 13 de Fevereiro de 2007 | · | Declaração inicial | Investimento passivo | SEC |
| Pessoa de relato não divulgada | 13 de Fevereiro de 2007 | · | Declaração inicial | Investimento passivo | SEC |
| Pessoa de relato não divulgada | 6 de Fevereiro de 2006 | · | Declaração inicial | Investimento passivo | SEC |
| Pessoa de relato não divulgada | 27 de Dezembro de 2005 | · | Declaração inicial | Investimento passivo | SEC |
| Pessoa de relato não divulgada | 27 de Dezembro de 2005 | · | Declaração inicial | Investimento passivo | SEC |
| Pessoa de relato não divulgada | 18 de Julho de 2005 | · | Declaração inicial | Investimento passivo | SEC |
| Pessoa de relato não divulgada | 22 de Abril de 2005 | · | Declaração inicial | Investimento passivo | SEC |
| Pessoa de relato não divulgada | 23 de Janeiro de 2004 | · | Declaração inicial | Investimento passivo | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Executivos da empresa 34 insiders · 18 diretores · 18 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Mark Strobeck | President and CEO | 1 de Julho de 2026 A | 62.349 | 0 | 0 | $0 |
| Russell H Ellison | President and Chief Executive Officer | 3 de Maio de 2021 A | 12.050 | 0 | 0 | $0 |
| Stuart M Paul | Chief Executive Officer | 4 de Setembro de 2019 F | 330.056 | 0 | 0 | $0 |
| CHIOINI ROBERT L | Chairman, President and CEO | 15 de Dezembro de 2017 M | 2.549.907 | 0 | 0 | $0 |
| Jesse Neri | SVP and CFO | 1 de Julho de 2026 A | 27.239 | 0 | 1 | $-744 |
| Russell Skibsted | EVP, Chief Financial Officer and Chief Business Officer | 9 de Setembro de 2022 A | · | 0 | 0 | $0 |
| Angus W. Smith | Chief Financial Officer | 28 de Novembro de 2019 F | 168.486 | 0 | 0 | $0 |
| Thomas E Klema | Vice President, CFO | 15 de Dezembro de 2017 M | 671.492 | 0 | 0 | $0 |
| Heather Hunter | Chief Operating Officer | 1 de Julho de 2026 A | 28.007 | 0 | 2 | $-5.822 |
| Megan C. Timmins | EVP, CLO & Secretary | 1 de Julho de 2026 A | 31.240 | 0 | 0 | $0 |
| Timothy Chole | SVP, Chief Commercial Officer | 20 de Maio de 2025 A | 122.855 | 0 | 0 | $0 |
| Marc L Hoffman | Chief Medical Officer | 17 de Março de 2023 A | 25.665 | 0 | 0 | $0 |
| Paul E Mcgarry | SVP, Finance and CAO | 17 de Março de 2023 A | 28.515 | 0 | 0 | $0 |
| Raymond Dennis Pratt | Chief Development Officer | 3 de Maio de 2021 A | 353.358 | 0 | 0 | $0 |
| Ajay Gupta | Sr. VP & Chief Scientific Off. | 26 de Abril de 2020 F | 574.700 | 0 | 0 | $0 |
| David Kull | Principal Accounting Officer | 25 de Abril de 2019 A | 13.270 | 0 | 0 | $0 |
| Annamaria T Kausz | VP of Drug Development | 23 de Setembro de 2011 A | · | 0 | 0 | $0 |
| Richard C Yocum | VP - Clin. Dev. & Med. Affairs | 15 de Janeiro de 2010 A | · | 0 | 0 | $0 |
| Joseph H Dawson | Conselheiro | 1 de Julho de 2026 A | 12.133 | 0 | 0 | $0 |
| Joan Lau | Conselheiro | 1 de Julho de 2026 A | 20.944 | 0 | 0 | $0 |
| Robert S Radie | Conselheiro | 1 de Julho de 2026 A | 23.985 | 0 | 0 | $0 |
| Allen Nissenson | Conselheiro | 1 de Julho de 2026 A | 23.892 | 0 | 0 | $0 |
| John G Cooper | Conselheiro | 1 de Julho de 2026 A | 23.670 | 0 | 1 | $-4.419 |
| Andrea Heslin Smiley | Conselheiro | 20 de Maio de 2025 A | 142.062 | 0 | 0 | $0 |
| Mark H Ravich | Conselheiro | 20 de Maio de 2025 A | 148.831 | 0 | 0 | $0 |
| John Peter Mclaughlin | Conselheiro | 17 de Junho de 2021 A | 136.974 | 0 | 0 | $0 |
| Benjamin Wolin | Conselheiro | 6 de Junho de 2019 A | 27.710 | 0 | 0 | $0 |
| Robin L Smith | Conselheiro | 6 de Junho de 2019 A | 31.366 | 0 | 0 | $0 |
| Lisa N Colleran | Conselheiro | 6 de Junho de 2019 A | 18.674 | 0 | 0 | $0 |
| Patrick J Bagley | Conselheiro | 19 de Março de 2018 A | 116.307 | 0 | 0 | $0 |
| Ronald D Boyd | Conselheiro | 19 de Março de 2018 A | 42.678 | 0 | 0 | $0 |
| Kenneth L Holt | Conselheiro | 16 de Março de 2017 S | 12.630 | 0 | 0 | $0 |
| Irrevocable Larson Family Investment Trust | Detentor de 10% | 11 de Abril de 2025 P | 3.557.500 | 0 | 0 | $0 |
| HAGELSTEIN DAVID A | Detentor de 10% | 28 de Janeiro de 2013 J | 1.360.700 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Participação em ETFs Detido por 2 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
RMTI Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
classificação · 8 analistas
COMPRA
Alvo mediano
$20.00
+131,2%
2 25,0%
Compra forte
5 62,5%
Compra
1 12,5%
Manter
0 0,0%
Venda
0 0,0%
Venda forte
Preço-alvo de 12 meses
2 analistas · 2026-10-03Alvo médio $20.00 +131,2%
Mín$20.00
Média$20.00
Máx$20.00
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
Base do ano fiscal, preços no fechamento do último ano fiscal de cada empresa.
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| RMTI | $33M | -5.5 | -31.8% | -7.7% | -15.8% | 16.9% |
| UTMD | $178M | 16.1 | -5.8% | 29.3% | 9.5% | 57.1% |
| RXST | $430M | -11.0 | -3.9% | -29.0% | -14.0% | 76.6% |
| SKYA | · | · | · | · | · | · |
| TELA | $53M | -1.4 | 15.8% | -48.4% | -501.1% | 67.7% |
| NSPR | $77M | -2.3 | 28.1% | -543.3% | -129.3% | 29.5% |
| ADVB | $15M | -4.4 | · | · | -159.1% | · |
| LUCY | · | · | · | · | · | · |
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
Escolha as métricas que importam para si — clique no + ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Fonte: SEC 10-Q arquivado Ago 13, 2026